The use and interpretation of P values in the biomedical literature is problematic. The importance of a study is often inappropriately defined by the P value. This problem is highlighted by the use of "trend" to refer to statistically nonsignificant results. There is no definition of a trend toward statistical significance and, therefore, describing "almost significant" results as a trend introduces substantial subjectivity and the opportunity for biased reporting language that could mislead a reader (eg, assuming P < .10). To deemphasize P values, some journals prohibit the use of statements about a trend toward significance. 1 Instead, presentation and discussion of observed differences and their uncertainty (eg, CIs) are encouraged. Point Illustrated "There was a trend toward long-term survival in favor of GemErlo (estimated survival after 1, 2, and 5 y for GemErlo was 77%, 53%, and 25% vs 79%, 54%, and 20% for Gem, respectively)." Large P value and comparator statistics to support trend statement found only in appendix "Women with stage I-II PBL had overall survival superior to women with stage I-II systemic presentations of the same lymphoma subtype (Figure 4) , except for ALCL-PBL where the same trend was seen, although not statistically significant at the 5% level." Trend statement highlighted in Key Points section and as primary study conclusion (abstract) without mention of potentially clinically relevant effect size
Abbreviations: ABC, activated B cell; ALCL, anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; GCB, germinal center B cell; Gem, gemcitabine; GemErlo, gemcitabine and erlotinib; HCC, hepatocellular carcinoma; HR, hazard ratio; PBL, primary breast lymphoma; PFS, progression-free survival; OS, overall survival.
notable differences across journals, with 14.4% (47 of 326) of articles in the JCO, 6.5% (8 of 124) of articles in the JNCI, 4.0% (6 of 149) of articles in JAMA Oncology, and 1.6% (2 of 123) of articles in Lancet Oncology using at least 1 statement describing a trend toward significance (Figure) . Problematic uses of such statements are described in the Table. 2-5
There were 125 instances where a trend statement was used to describe a statistically nonsignificant result across 63 articles. Eleven statements (8.8%) provided no data by which to evaluate the magnitude of difference between groups (eg, hazard ratio). Of the 86 instances where a P value was presented, 35 (40.7%) were P ≥ .10 (15 [17.4%] were P ≥ .10 to P < .20, 13 [15.1%] were P ≥ .20 to P < .50, and 7 [8.1%] were P ≥ .50).
Discussion | We found that trend statements are frequently used to describe statistically nonsignificant results, commonly with large P values and minimal supporting data. In addition, when P values approached statistical significance, promising clinical significance was often deemphasized to highlight the proximity of the P value to .05. This finding highlights an overemphasis on P values in the reporting of data in the oncology literature.
The biomedical literature currently has a problem with P values. In response to this problem, the American Statistical Association released a statement outlining primary P value principles.
6 Among these principles were the following:
(1) scientific conclusions should not be based solely on a P value threshold, (2) a P value does not measure the importance of a result, and (3) a P value does not provide a good measure of evidence regarding a hypothesis. Trend statements violate these principles. We must deemphasize P values and shift our focus to the clinical relevance of the finding (eg, the magnitude of the result along with CIs), the power of the study to address a clinically meaningful difference, and the appropriateness of the study design. This shift is additionally important to address the overinterpretation of statistically significant but clinically meaningless findings. As others have proposed, increased methodological and statistical training of scientists and clinicians may enhance the quality of data analysis, reporting, and interpretation. The oncology research community-in particular, leading oncology research journals-should take the lead in implementing the highest standards for reporting of results. 
Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care
In 2010, the US Food and Drug Administration established an approval pathway for biosimilar agents, biological agents with an active ingredient highly similar to the reference biological agent, to facilitate drug competition and lower costs. It is unclear whether biosimilar drugs could yield large cost savings in the United States given the previously documented market and regulatory barriers. [1] [2] [3] Moreover, few studies have investigated the real-world safety and effectiveness profile of biosimilar agents compared with that of brand-name (reference) biological agents. The colony-stimulating growth factors (CSF) filgrastimsndz and tbo-filgrastim reduce risk of chemotherapyinduced neutropenia and were the first biosimilar agents approved in the United States. We examined the incidence of febrile neutropenia (FN), CSF-related adverse events (AEs), and drug cost among commercially insured US patients with cancer treated with chemotherapy.
Methods | This retrospective observational study analyzed administrative health claims data from a large commercially insured population. Only deidentified data were used, and the study was exempt from review by an institutional review board. 
